A review of the possible mechanisms of action of tocotrienol - A potential antiosteoporotic agent

Current Drug Targets

Volumn 14, Issue 13, 2013, Pages 1533-1541

  Chin, Kok Yong ^a   Mo, Huanbiao ^b   Soelaiman, Ima Nirwana ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Bone remodeling; Osteoblast; Osteoclast; Osteoporosis; Tocotrienol

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; BONE MORPHOGENETIC PROTEIN 2; CATENIN; COLONY STIMULATING FACTOR 1; FIBROBLAST GROWTH FACTOR 23; GAMMA TOCOTRIENOL; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 7; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS; PROTEIN KINASE B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCAVENGER; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WNT PROTEIN; BONE DENSITY CONSERVATION AGENT; TOCOPHEROL;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; LYMPHOCYTE TRANSFORMATION; MESENCHYMAL STEM CELL; META ANALYSIS (TOPIC); NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PRENYLATION; TISSUE DIFFERENTIATION; UPREGULATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; WNT SIGNALING PATHWAY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; GENE EXPRESSION REGULATION; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; TOCOPHEROLS; TOCOTRIENOLS; WNT SIGNALING PATHWAY;

EID: 84889069201     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990178     Document Type: Article

References (110)

1. Doran PM, Khosla S. Osteoporosis. In: Hall JE, Nieman LK,editors. Contemporary Endocrinology: Handbook of Diagnostic Endocrinology. Totowa, New Jersey: Humana Press Inc. 2003. p. 257-75.
2. Handa R, Ali Kalla A, Maalouf G. Osteoporosis in developingcountries. Best Pract Res Clin Rheumatol 2008; 22(4): 693-708.
3. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and Economic Burden of OsteoporosisRelated Fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22(3): 465-75.
4. Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011; 6(1-2): 59-155.
5. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Cnter JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301(5): 513-21.
6. Papaioannou A, Kennedy CC, Ioannidis G, et al. The impact ofincident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2009; 20(5): 703-14.
7. Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanismsof action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003; 37(4): 225-38.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefitsof estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-33.
9. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolictherapies for osteoporosis. N Engl J Med 2007; 357(9): 905-16.
10. Strampel W, Emkey R, Civitelli R. Safety considerations withbisphosphonates for the treatment of osteoporosis. Drug Saf 2007; 30(9): 755-63.
11. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures: An Updated Meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155(12): 827-38.
12. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calciumsupplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011; 342: d2040.
13. Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol 2010; 80(11): 1613-31.
14. Tan B. Appropriate Spectrum Vitamin E and New Perspectives onDesmethyl Tocopherols and Tocotrienols. JANA 2005; 8(1): 35-42.
15. Muhammad N, Luke DA, Shuid AN, Mohamed N, Soelaiman I-N. Two Different Isomers of Vitamin E Prevent Bone Loss in Postmenopausal Osteoporosis Rat Model. Evid Based Complement Alternat Med 2012; 2012(Article ID 161527). Available from: http://dx.doi.org/10.1155/2012/161527.
16. Soelaiman IN, Ming W, Abu Bakar R, et al. Palm TocotrienolSupplementation Enhanced Bone Formation in OestrogenDeficient Rats. Int J Endocrinol. 2012; 2012(Article ID 532862). Available from: http://dx.doi.org/10.1155/2012/532862.
17. Aktifanus AT, Shuid AN, Rashid NH, et al. Comparison of theEffects of Tocotrienol and Estrogen on the Bone Markers and Dynamic Changes in Postmenopausal Osteoporosis Rat Model. Asian J Anim Vet Adv 2012; 7(3): 225-34.
18. Nazrun A, Khairunnur A, Norliza M, Norazlina M, Ima Nirwana S. Effects of palm tocotrienol on oxidative stress and bone strength in ovariectomised rats. Med & Health 2008; 3(2): 83-90.
19. Norazlina M, Ima Nirwana S, Abd, Gapor M, Khalid B. Palmvitamin E is comparable to alpha-tocotrienol in maintaining bone mineral density in ovariectomised female rats. Exp Clin Endocrinol Diabetes 2000; 108: 1-6.
20. Ima Nirwana S, Kiftiah A, Zainal A, Norazlina M, Abd Gapor M, Khalid BAK. Palm vitamin e prevents osteoporosis in orchidectomised growing male rats. Nat Prod Sci 2000; 6(4): 155-60.
21. Hermizi H, Faizah O, Ima-Nirwana S, Ahmad Nazrun S, Norazlina M. Beneficial Effects of Tocotrienol and Tocopherol on Bone Histomorphometric Parameters in Sprague-Dawley Male Rats After Nicotine Cessation. Calcif Tissue Int 2009; 84(1): 65-74.
22. Norazlina M, Hermizi H, Faizah O, Ima-Nirwana S. Vitamin Ereversed nicotine-induced toxic effects on bone biochemical markers in male rats. Arch Med Sci 2010; 6(4): 505-12.
23. Ima Nirwana S, Suhaniza S. Effects of tocopherols and tocotrienolson body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone. J Med Food 2004; 7(1): 45-51.
24. Ima-Nirwana S, Fakhrurazi H. Palm vitamin E protects boneagainst Dexamethasone-induced osteoporosis in male rats. Med J Malaysia 2002; 57(2): 133-41.
25. Ahmad NS, Khalid BAK, Luke DA, Ima Nirwana S. Tocotrienoloffers better protection than tocopherol from free radical-induced damage of rat bone. Clin Exp Pharmacol Physiol 2005; 32(9): 761-70.
26. Mehat M, Shuid A, Mohamed N, Muhammad N, Soelaiman I. Beneficial effects of vitamin E isomer supplementation on static and dynamic bone histomorphometry parameters in normal male rats. J Bone Miner Metab 2010; 28(5): 503-9.
27. Shuid A, Mehat Z, Mohamed N, Muhammad N, Soelaiman I. Vitamin E exhibits bone anabolic actions in normal male rats. J Bone Miner Metab 2010; 28(2): 149-56.
28. Arjmandi BH, Juma S, Beharka A, Bapna MS, Akhter M, Meydani SN. Vitamin E improves bone quality in the aged but not in young adult male mice. J Nutr Biochem 2002; 13(9): 543-9.
29. Smith BJ, Lucas EA, Turner RT, et al. Vitamin E ProvidesProtection for Bone in Mature Hindlimb Unloaded Male Rats. Calcif Tissue Int 2005; 76(4): 272-9.
30. Chai S, Wei C, Brummel-Smith K, Arjmandi B. The role ofvitamin E in reversing bone loss. Aging Clin Exp Res 2008; 20(6): 521-7.
31. Deyhim F, Garcia C, Villareal A, et al. Vitamin E does not supportbone quality in orchidectomised rats. Curr Nutr Food Sci 2007; 3: 300-3.
32. Fujita K, Iwasaki M, Ochi H, et al. Vitamin E decreases bone massby stimulating osteoclast fusion. Nat Med 2012; 18: 589-94.
33. Chin K-Y, Ima-Nirwana S. Vitamin E as an AntiosteoporoticAgent via Receptor Activator of Nuclear Factor Kappa-B Ligand Signaling Disruption: Current Evidence and Other Potential Research Areas. Evid Based Complement Alternat Med. 2012; 2012 (Article ID 747020). Available from: http://dx.doi.org/10.1155/2012/747020.
34. Sommerfeldt D, Rubin C. Biology of bone and how it orchestratesthe form and function of the skeleton. Eur Spine J 2001; 10(2): S86-S95.
35. Hadjidakis DJ, Androulakis II. Bone Remodeling. Ann N Y AcadSci 2006; 1092(1): 385-96.
36. Raisz LG. Physiology and Pathophysiology of Bone Remodeling. Clin Chem 1999; 45(8): 1353-8.
37. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within bone controls bone remodeling. Bone 2009; 44(6): 1026-33.
38. Caetano-Lopes J, Canhao H, Fonseca JE. Osteoblasts and boneformation. Acta Reumatol Port 2007; 32(2): 103-10.
39. Riggs BL, Khosla S, III LJM. Sex Steroids and the Constructionand Conservation of the Adult Skeleton. Endocr Rev 2002; 23(3): 279-302.
40. Chin KY, Ima-Nirwana S. Sex Steroids and Bone Health Status inMen. Int J Endocrinol. 2012; 2012 (Article ID 208719). Available from: http://www.hindawi.com/journals/ije/2012/208719/.
41. Saidak Z, Marie PJ. Strontium signaling: Molecular mechanismsand therapeutic implications in osteoporosis. Pharmacol Ther 2012; 136(2): 216-26.
42. Komori T. Regulation of osteoblast differentiation by transcriptionfactors. J Cell Biochem 2006; 99(5): 1233-9.
43. Uto-Kondo H, Ohmori R, Kiyose C, et al. Tocotrienol suppressesadipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J Nutr 2009; 139(1): 51-7.
44. Ahn KH, Jung HK, Jung SE, et al. Microarray Analysis of GeneExpression During Differentiation of Human Mesenchymal Stem Cells Treated with Vitamin E in vitro into Osteoblasts. Korean J Bone Metab 2011; 18(1): 23-32.
45. Abukhadir SSA, Mohamed N, Makpol S, Muhammad N. Effects ofPalm Vitamin E on Bone-Formation-Related Gene Expression in Nicotine-Treated Rats. Evid Based Complement Alternat Med 2012; 2012 (Article ID 656025). Available from: http://dx.doi.org/10.1155/2012/656025.
46. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast andosteoclast differentiation. Oral Dis 2002; 8(3): 147-59.
47. Baron R, Horne W. Regulation of Osteoclast Activity. In: BronnerF, Farach-Carson M, Rubin J, editors. Bone Resorption: Springer London; 2005. p. 34-57.
48. Brooks R, Kalia P, Ireland D, Beeton C, Rushton N. Directinhibition of osteoclast formation and activity by the vitamin E isomer gamma-tocotrienol. Int J Vitam Nutr Res 2011; 81(6): 358-67.
49. Ha H, Lee J-H, Kim H-N, Lee ZH. Tocotrienol inhibitsosteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. Biochem Biophys Res Commun 2011; 406(4): 546-51.
50. Lee J-H, Kim H-N, Yang D, et al. Trolox PreventsOsteoclastogenesis by Suppressing RANKL Expression and Signaling. J Biol Chem 2009; 284(20): 13725-34.
51. Norazlina M, Maizatul-Neza J, Azarina A, Nazrun A, Norliza M, Ima-Nirwana S. Effects of vitamin E on receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in rats treated with nicotine. Med J Malaysia 2010; 65(1): 14-7.
52. Chen P-Y, Sun J-S, Tsuang Y-H, Chen M-H, Weng P-W, Lin F-H. Simvastatin promotes osteoblast viability and differentiation viaRas/Smad/Erk/BMP-2 signaling pathway. Nutr Res 2010; 30(3): 191-9.
53. Pagkalos J, Cha JM, Kang Y, Heliotis M, Tsiridis E, Mantalaris A. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res 2010; 25(11): 2470-8.
54. Yang F, Zhao S-f, Zhang F, He F-m, Yang G-L. Simvastatin-loadedporous implant surfaces stimulate preosteoblasts differentiation: an in vitro study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111(5): 551-6.
55. Das UN. Nitric Oxide as the Mediator of the AntiosteoporoticActions of Estrogen, Statins, and Essential Fatty Acids. Exp Biol Med 2002; 227(2): 88-93.
56. Jadhav SB, Jain GK. Statins and osteoporosis: new role for olddrugs. J Pharm Pharmacol 2006; 58(1): 3-18.
57. Mo H, Yeganehjoo H, Shah A, Mo WK, Soelaiman IN, Shen C-L. Mevalonate-suppressive dietary isoprenoids for bone health. J Nutr Biochem 2012; 23(12): 1543-51.
58. Staal A, Frith JC, French MH, et al. The Ability of Statins toInhibit Bone Resorption Is Directly Related to Their Inhibitory Effect on HMG-CoA Reductase Activity. J Bone Miner Res 2003; 18(1): 88-96.
59. Grasser WA, Baumann AP, Petras SF, et al. Regulation ofosteoclast differentiation by statins. J Musculoskel Neuron Interact 2003; 3(1): 53-62.
60. Kaji H, Kanatani M, Sugimoto T, Chihara K. Statins Modulate theLevels of Osteoprotegerin/Receptor Activator of NF B Ligand mRNA in Mouse Bone-cell Cultures. Horm Metab Res 2005; 37(10): 589-92.
61. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factorB ligand through modulation of NFB pathway. Int J Cancer 2008; 123(8): 1733-40.
62. Yamashita M, Otsuka F, Mukai T, et al. Simvastatin inhibitsosteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling. Regul Pept 2010; 162(1-3): 99-108.
63. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects ofstatins on bone mineral density: a meta-analysis of clinical studies. Bone 2007; 40(6): 1581-7.
64. Bauer D, Mundy G, Jamal S, et al. Use of statins and fracture:Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164(2): 146-52.
65. Song B-L, DeBose-Boyd RA. Insig-dependent Ubiquitination andDegradation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Stimulated by-and-Tocotrienols. J Biol Chem 2006; 281(35): 25054-61.
66. Khor HT, Chieng DY, Ong KK. Tocotrienols inhibit liver HMGCoA reductase activity in the guinea pig. Nutr Res 1995; 15(4): 537-44.
67. Qureshi A, Reis J, Qureshi N, Papasian C, Morrison D, Schaefer D. delta-Tocotrienol and quercetin reduce serum levels of nitric oxide and lipid parameters in female chickens. Lipids Health Dis 2011; 10(1): 39.
68. Qureshi AA, Peterson DM. The combined effects of noveltocotrienols and lovastatin on lipid metabolism in chickens. Atheroscler 2001; 156(1): 39-47.
69. Yu S, Thomas A, Gapor A, Tan B, Qureshi N, Qureshi A. Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens. Lipids 2006; 41(5): 453-61.
70. Wali V, Bachawal S, Sylvester P. Suppression in MevalonateSynthesis Mediates Antitumor Effects of Combined Statin and-Tocotrienol Treatment. Lipids 2009; 44(10): 925-34.
71. Guthrie N, Chambers AF, Gapor A, Carroll KK. Effect of palm oiltocotrienols on the proliferation of /MS-transformed NIH-3T3 cells and on farnesyl: And geranylgeranyl protein transferase activity. FASEB J 1996; 10(3).
72. Abdul-Majeed S, Mohamed N, Soelaiman I-N. Effects ofTocotrienol and Lovastatin Combination on Osteoblast and Osteoclast Activity in Estrogen-Deficient Osteoporosis. Evid Based Complement Alternat Med 2012; 2012 (Article ID 960742). Available from: http://dx.doi.org/10.1155/2012/960742.
73. Khor H, Ng T. Effects of administration of a-tocopherol andtocotrienols on serum lipids and liver HMG CoA reductase activity. Int J Food Sci Nutr 2000; 51(Supplement): S3-S11.
74. Bai X-c, Lu D, Bai J, et al. Oxidative stress inhibits osteoblasticdifferentiation of bone cells by ERK and NFB. Biochem Biophys Res Commun 2004; 314(1): 197-207.
75. Li M, Zhao L, Liu J, et al. Hydrogen Peroxide Induces G2 CellCycle Arrest and Inhibits Cell Proliferation in Osteoblasts. Anat Rec (Hoboken) 2009; 292(8): 1107-13.
76. Lee DH, Lim BS, Lee YK, Yang HC. Effects of hydrogen peroxide(H2O2) on alkaline phosphatase activity and matrix mineralization of odontoblast and osteoblast cell lines. Cell Biol Toxicol 2006; 22(1): 39-46.
77. Abd Manan N, Mohamed N, Shuid AN. Effects of Low-Doseversus High-Dose Gamma-tocotrienol on the Bone Cells Exposed to the Hydrogen Peroxide-Induced Oxidative Stress and Apoptosis. Evid Based Complement Alternat Med. 2012; 2012 (Article ID 680834). Available from: http://dx.doi.org/10.1155/2012/680834.
78. Bai X-c, Lu D, Liu A-l, et al. Reactive Oxygen Species StimulatesReceptor Activator of NFB Ligand Expression in Osteoblast. J Biol Chem 2005; 280(17): 17497-506.
79. Almeida M, Han L, Ambrogini E, Bartell SM, Manolagas SC.Oxidative Stress Stimulates Apoptosis and Activates B in Osteoblastic Cells via a PKC /p66shc Signaling Cascade: Counter Regulation by Estrogens or Androgens. Mol Endocrinol 2010; 24(10): 2030-7.
80. Packer L, Weber SU, Rimbach G. Molecular Aspects of-Tocotrienol Antioxidant Action and Cell Signalling. J Nutr 2001; 131(2): 369S-73S.
81. Begum N, Terao J. Protective Effect of Alpha-tocotrienol againstFree Radical-Induced Impairment of Erythrocyte Deformability. Biosci Biotechnol Biochem 2002; 66(2): 398-403.
82. Nizar A, Ahmad Nazrun S, Norazlina M, Norliza M, Ima Nirwana S. Low dose of tocotrienols protects osteoblasts against oxidative stress. Clin Ter 2011; 162(6): 533-8.
83. Yamasaki N, Tsuboi H, Hirao M, Nampei A, Yoshikawa H, Hashimoto J. High oxygen tension prolongs the survival of osteoclast precursors via macrophage colony-stimulating factor. Bone 2009; 44(1): 71-9.
84. Jung K-A, Kwak M-K. The Nrf2 System as a Potential Target forthe Development of Indirect Antioxidants. Molecules 2010; 15(10): 7266-91.
85. Khan NM, Sandur SK, Checker R, Sharma D, Poduval TB, Sainis KB. Pro-oxidants ameliorate radiation-induced apoptosis through activation of the calcium-ERK1/2-Nrf2 pathway. Free Radic Biol Med 2011; 51(1): 115-28.
86. Rana T, Schultz MA, Freeman ML, Biswas S. Loss of Nrf2accelerates ionizing radiation-induced bone loss by upregulating RANKL. Free Radic Biol Med 2012; 53(12): 2298-307.
87. Hsieh T-C, Elangovan S, Wu JM. Differential Suppression ofProliferation in MCF-7 and MDA-MB-231 Breast Cancer Cells Exposed to-,-and-Tocotrienols Is Accompanied by Altered Expression of Oxidative Stress Modulatory Enzymes. Anticancer Res 2010; 30(10): 4169-76.
88. Ha H, Bok Kwak H, Woong Lee S, et al. Reactive oxygen speciesmediate RANK signaling in osteoclasts. Exp Cell Res 2004; 301(2): 119-27.
89. Maniam S, Mohamed N, Shuid AN, Soelaiman IN. PalmTocotrienol Exerted Better Antioxidant Activities in Bone than-Tocopherol. Basic Clin Pharmacol Toxicol 2008; 103(1): 55-60.
90. Nazrun AS, Norazlina M, Norliza M, Nirwana SI. The Anti-Inflammatory Role of Vitamin E in Prevention of Osteoporosis. Adv Pharmacol Sci 2012; 2012 (Article ID 142702): 7 pages.
91. Lee S-K, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 2006; 38(5): 678-85.
92. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32(1): 1-7.
93. Rozen N, Ish-Shalom S, Rachmiel A, Stein H, Lewinson D. Interleukin-6 modulates trabecular and endochondral bone turnover in the nude mouse by stimulating osteoclast differentiation. Bone 2000; 26(5): 469-74.
94. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 2000; 96(5): 1873-8.
95. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFPotently Activates Osteoclasts, through a Direct Action Independent of and Strongly Synergistic with RANKL. Endocrinology 2002; 143(3): 1108-18.
96. Kobayashi K, Takahashi N, Jimi E, et al. Tumor Necrosis FactorStimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Rankl-Rank Interaction. J Exp Med 2000; 191(2): 275-86.
97. Qureshi A, Tan X, Reis J, et al. Inhibition of nitric oxide in LPS-stimulated macrophages of young and senescent mice by deltatocotrienol and quercetin. Lipids Health Dis 2011; 10(1): 239.
98. Yam M-L, Abdul Hafid S, Cheng H-M, Nesaretnam K. Tocotrienols Suppress Proinflammatory Markers and Cyclooxygenase-2 Expression in RAW264.7 Macrophages. Lipids 2009; 44(9): 787-97.
99. Qureshi A, Reis J, Papasian C, Morrison D, Qureshi N. Tocotrienols inhibit lipopolysaccharide-induced pro-inflammatory cytokines in macrophages of female mice. Lipids Health Dis 2010; 9(1): 143.
100. Norazlina M, Lee P, Lukman H, Nazrun A, Ima-Nirwana S. Effects of vitamin E supplementation on bone metabolism in nicotine-treated rats. Singapore Med J 2007; 48(3): 195-9.
101. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116(5): 1202-9.
102. Mbalaviele G, Sheikh S, Stains JP, et al.-Catenin and BMP-2synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 2005; 94(2): 403-18.
103. Glass Ii DA, Bialek P, Ahn JD, et al. Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation. DevCell 2005; 8(5): 751-64.
104. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt Proteins Prevent Apoptosis of Both Uncommitted OsteoblastProgenitors and Differentiated Osteoblasts by-Catenin-dependent and-independent Signaling Cascades Involving Src/ERK and Phosphatidylinositol 3-Kinase/AKT. J Biol Chem 2005; 280(50): 41342-51.
105. Xu W, Du M, Zhao Y, Wang Q, Sun W, Chen B.-Tocotrienolinhibits cell viability through suppression of-catenin/Tcfsignaling in human colon carcinoma HT-29 cells. J Nutr Biochem 2012; 23(7): 800-7.
106. Zhang J-S, Li D-M, He N, et al. A paraptosis-like cell death induced by-tocotrienol in human colon carcinoma SW620 cells isassociated with the suppression of the Wnt signaling pathway. Toxicology 2011; 285(1-2): 8-17.
107. Li Y, Sun W-G, Liu H-K, et al.-Tocotrienol inhibits angiogenesisof human umbilical vein endothelial cell induced by cancer cell. JNutr Biochem 2011; 22(12): 1127-36.
108. Hinoi E, Fujimori S, Wang L, Hojo H, Uno K, Yoneda Y. Nrf2 Negatively Regulates Osteoblast Differentiation via Interferingwith Runx2-dependent Transcriptional Activation. J Biol Chem 2006; 281(26): 18015-24.
109. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26(2): 229-38.
110. Neve A, Corrado A, Cantatore FP. Osteocytes: central conductors of bone biology in normal and pathological conditions. Acta Physiol (Oxf) 2012; 204(3): 317-30.